SpaceX closed below its $135 IPO price this week for the first time since the stock began trading, marking a 42% decline from the post-listing peak and erasing roughly $88 billion in paper value across the shareholder base. Thursday night's Starship launch abort—a countdown halt with seconds remaining—offered no technical reprieve, leaving shares flat in Friday premarket.

The IPO priced at $135 per share last month, valuing the combined space and AI operations at approximately $210 billion. Shares spiked in early trading before reversing course as institutional buyers reassessed timelines for Starlink's direct-to-device revenue and Starship's orbital refueling milestones. Short interest has built steadily since mid-month, with three separate data vendors reporting net short positions exceeding $4.2 billion notional as of Wednesday's close. The abort sequence—triggered by a propellant loading anomaly at T-minus 8 seconds—extends a pattern of schedule slippage that has now pushed the first orbital refueling demonstration into Q3 at the earliest.

The valuation pressure reflects a sobering recalibration. SpaceX's business case rests on Starship achieving full reusability at commercial cadence, enabling the economics that justify Starlink V3 deployment and NASA's Artemis lander contract. Each launch delay compounds the timeline risk: Starlink's satellite replacement cycle assumes 120+ Starship flights annually by 2026, a figure that requires flawless operational tempo beginning this quarter. The company has completed four Starship test flights to date, none achieving orbit with payload recovery. Meanwhile, competitor Blue Origin is reportedly within six months of New Glenn's first orbital insertion, narrowing SpaceX's reusable heavy-lift monopoly.

Short sellers are pricing in execution risk, but the thesis extends beyond hardware. SpaceX's AI division—folded into the same equity structure—was ascribed roughly $40 billion of the IPO valuation based on xAI's Grok model and data center ambitions. That premium now looks thin against OpenAI's $300 billion private round and Anthropic's reported $60 billion discussions. The AI narrative was meant to derisk the equity for generalist allocators; instead, it has imported a second vector of uncertainty tied to Musk's allocation of engineering talent between rocket development and model training.

Allocators should monitor three near-term catalysts. First, the next Starship launch window opens Monday through Wednesday next week, pending FAA clearance on the propellant anomaly. A clean flight to orbit would likely trigger short covering and restore the $150-$160 technical range. Second, Starlink's Q1 earnings call is scheduled for late April, where management will address subscriber growth in Europe and direct-to-device partnership economics with T-Mobile. Third, NASA's Artemis III timeline review—expected mid-May—will clarify whether the 2026 lunar landing remains feasible or slips, directly impacting the $2.9 billion contract milestone payments.

SpaceX has 68 Falcon launches on manifest through year-end, each generating approximately $70 million in visible revenue. That operational cadence remains intact and continues to fund Starship development at a reported $2 billion annual burn rate. The equity question is whether patient capital will tolerate another 18-24 months of Starship iteration, or whether the IPO window has permanently closed on speculative deep-tech at these multiples. Blue Origin's New Glenn flies in Q3.